Brokerages Set Immix Biopharma, Inc. (NASDAQ:IMMX) PT at $20.71

Immix Biopharma, Inc. (NASDAQ:IMMX) has earned a consensus recommendation of “Moderate Buy” from the ten research firms that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and eight have assigned a buy recommendation to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $21.2857.

A number of equities research analysts recently weighed in on IMMX shares. Needham & Company LLC assumed coverage on Immix Biopharma in a report on Wednesday, July 22nd. They set a “buy” rating and a $21.00 price target for the company. Morgan Stanley reduced their price objective on Immix Biopharma from $20.00 to $19.00 and set an “overweight” rating on the stock in a research note on Tuesday. Lifesci Capital began coverage on Immix Biopharma in a report on Wednesday, June 17th. They set an “outperform” rating and a $19.00 target price on the stock. HC Wainwright raised their target price on Immix Biopharma from $20.00 to $25.00 and gave the company a “buy” rating in a research note on Monday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immix Biopharma in a report on Friday, July 17th.

Immix Biopharma News Roundup

Here are the key news stories impacting Immix Biopharma this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and a $25 price target. The firm expects Immix Biopharma’s quarterly losses to narrow through 2027, turning to projected positive EPS of $0.31 in the fourth quarter of 2027. HC Wainwright earnings estimates and rating
• Positive Sentiment: Analysts remain broadly bullish on Immix Biopharma, with a reported consensus price target of approximately $20.71. That outlook implies meaningful potential appreciation if the company executes on its clinical and business plans. Immix Biopharma receives consensus target price
• Positive Sentiment: A separate report also highlighted Immix Biopharma among healthcare stocks viewed favorably by analysts, reinforcing the constructive sell-side sentiment surrounding IMMX. Analysts are bullish on Immix Biopharma
• Neutral Sentiment: HC Wainwright projects continued losses in 2026 and most of 2027, including estimated FY2026 EPS of $(0.72) and FY2027 EPS of $(0.20). The forecast for a return to profitability remains several quarters away.
• Negative Sentiment: HC Wainwright reduced its FY2026 EPS forecast from $(0.62) to $(0.72), cut its Q3 2026 estimate from $(0.14) to $(0.17), and lowered its Q4 2026 estimate from $(0.15) to $(0.19). These revisions signal weaker near-term earnings expectations despite the unchanged Buy rating and price target.
• Negative Sentiment: Pomerantz LLP announced an investigation into potential claims on behalf of Immix Biopharma investors. The development could create legal, reputational, and financial uncertainty for the company. Pomerantz investor alert

Institutional Trading of Immix Biopharma

A number of hedge funds and other institutional investors have recently modified their holdings of IMMX. Compass Financial Management LLC bought a new position in Immix Biopharma in the 2nd quarter worth approximately $56,000. Allworth Financial LP bought a new stake in shares of Immix Biopharma during the second quarter worth $75,000. Blue Owl Capital Holdings LP bought a new stake in shares of Immix Biopharma during the second quarter worth $4,511,000. Tocqueville Asset Management L.P. acquired a new position in shares of Immix Biopharma during the second quarter valued at $913,000. Finally, BlackRock Inc. bought a new position in Immix Biopharma in the second quarter valued at about $30,827,000. Institutional investors and hedge funds own 11.26% of the company’s stock.

Immix Biopharma Trading Down 1.0%

Shares of Immix Biopharma stock opened at $11.37 on Thursday. The stock has a market capitalization of $618.64 million, a price-to-earnings ratio of -12.92 and a beta of 0.11. Immix Biopharma has a 1-year low of $1.94 and a 1-year high of $12.14. The firm’s 50-day moving average price is $9.52 and its two-hundred day moving average price is $8.98.

Immix Biopharma (NASDAQ:IMMX) last posted its quarterly earnings data on Friday, August 7th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.01). As a group, equities research analysts predict that Immix Biopharma will post -0.71 EPS for the current year.

About Immix Biopharma

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.